11 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 20 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 11, Active not recruiting 2, Recruiting 2, Terminated 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow Iohexol: new trials by email Literature Review of Iohexol trials Research Report on Iohexol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4515100 in Healthy Participants LY4515100 via SAD, LY4515100 via MAD, LY4515100 - Healthy | Phase 1 | Recruiting | Eli Lilly and Company | 123 | 2026-01-15 | 2026-07-29 |
| Development of a Bayesian Estimator for Calculating Plasma Iohexol Clearance Iohexol, pharmacokinetics - Kidney Function Test | Phase 1 | Unknown | Centre Hospitalier Universitaire de Saint Etienne | 48 | 2024-06-01 | 2024-04-29 |
| A Study of Effect of LY3556050 on Metformin in Healthy Participants LY3556050, Metformin, Iohexol - Healthy | Phase 1 | Completed | Eli Lilly and Company | 18 | 2022-11-15 | 2023-01-18 |
| A Study of LY3526318 in Healthy Male Japanese Participants LY3526318, Placebo, Iohexol - Healthy | Phase 1 | Withdrawn | Eli Lilly and Company | 2022-11-01 | 2026-09-08 | |
| MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution - Type 1 Diabetes, Diabetic Kidney Disease | Phase 1 | Recruiting | Kalie Tommerdahl | 60 | 2022-07-01 | 2025-06-13 |
| Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Infigratinib, Tamoxifen, Omnipaque 350 - Breast Cancer, HER2-negative Breast Cancer | Phase 1 | Terminated | Jennifer Lee Caswell-Jin | 4 | 2020-10-13 | 2026-02-12 |
| Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function Furosemide Injection, Creatinine Powder, Iohexol - Chronic Kidney Failure | Phase 1 | Completed | Instituto Nacional de Cardiologia Ignacio Chavez | 50 | 2020-03-03 | 2024-12-17 |
| Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol Biospecimen Collection, Carboplatin, Iohexol - Malignant Solid Neoplasm | Phase 1 | Active not recruiting | NRG Oncology | 350 | 2020-01-15 | 2026-08-07 |
| A Study of LY3556050 in Healthy Participants LY3556050, Placebo, Iohexol - Healthy | Phase 1 | Completed | Eli Lilly and Company | 34 | 2019-11-20 | 2020-08-19 |
| An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants BMS-986259, Placebo, P-Aminohippurate - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 132 | 2019-06-18 | 2021-04-09 |
| A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib on Metformin Tucatinib, Metformin, Iohexol - Drug-drug Interaction | Phase 1 | Completed | Seagen Inc. | 18 | 2019-02-12 | 2019-03-27 |
| A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects LXE408, Placebo, Iohexol - Visceral Leishmaniasis, Chagas Disease | Phase 1 | Completed | Novartis Pharmaceuticals | 88 | 2018-12-21 | 2026-09-09 |
| Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL - Diabetes Mellitus, Type 1, Nephropathy | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 50 | 2018-10-01 | 2022-04-20 |
| Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Renal Biopsy - Type 2 Diabetes Mellitus, Obesity | Phase 1 / Phase 2 | Active not recruiting | University of Colorado, Denver | 100 | 2018-10-01 | 2023-08-15 |
| Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL, Vertical Sleeve Gastrectomy - Type 2 Diabetes Mellitus, Obesity | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 24 | 2018-10-01 | 2026-01-12 |
| A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants Lanabecestat, Iohexol - Renal Insufficiency | Phase 1 | Withdrawn | Eli Lilly and Company | 2018-06-01 | 2018-06-28 | |
| A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants Abemaciclib, Metformin, Iohexol - Healthy | Phase 1 | Completed | Eli Lilly and Company | 40 | 2016-08-01 | 2019-01-04 |
| A Study of the Effect of RG1662 on Metformin in Healthy Volunteers Omnipaque 300, RG1662, metformin - Healthy Volunteer | Phase 1 | Completed | Hoffmann-La Roche | 17 | 2015-02-01 | 2016-11-02 |
| A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease Iohexol - Fabry Disease | Phase 1 | Terminated | Genzyme, a Sanofi Company | 39 | 2013-05-01 | 2020-12-16 |
| A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects GSK1349572, Placebo, Iohexol Injection - Infections, Human Immunodeficiency Virus and Tuberculosis | Phase 1 | Completed | ViiV Healthcare | 38 | 2010-10-01 | 2012-06-11 |
Diabetic Nephropathies (3) · Kidney Diseases (3) · Diabetes Complications (2) · Diabetes Mellitus, Type 1 (2) · Diabetes Mellitus, Type 2 (2) · Obesity (2) · Pediatric Obesity (2) · Acquired Immunodeficiency Syndrome (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Chagas Disease (1) · Diabetes Mellitus (1) · Fabry Disease (1) · Infections (1) · Insulin Resistance (1)
Eli Lilly and Company (6) · University of Colorado, Denver (3) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Genzyme, a Sanofi Company (1) · Hoffmann-La Roche (1) · Instituto Nacional de Cardiologia Ignacio Chavez (1) · Jennifer Lee Caswell-Jin (1) · Kalie Tommerdahl (1) · NRG Oncology (1) · Novartis Pharmaceuticals (1) · Seagen Inc. (1) · ViiV Healthcare (1)
United States (15) · United Kingdom (3) · France (2) · Argentina (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Finland (1) · Hungary (1) · Japan (1) · Mexico (1) · Netherlands (1) · Norway (1) · Poland (1)
Petter Bjornstad, MD (3) · Jennifer Lee Caswell-Jin (1) · JoAl Mayor, PharmD, BCOP (1) · Sarah E Taylor (1)
PMID 32737116, PMID 35507146, PMID 36623423, PMID 39368039, PMID 40126554, PMID 41708511
2014 (1), K08CA252457 (1), K23HL159292 (1), U10CA180868 (1)